For the quarter ending 2025-09-30, KAPA has $8,066K in assets. $5,575K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 5,575 | 3,034 | ||
| Vendor advances, gross | 3,271 | - | ||
| Less accumulated amortization | 2,214 | - | ||
| Vendor advances, net | 1,057 | 1,717 | ||
| Prepaid expenses and other current assets | 24 | 88 | ||
| Total current assets | 6,656 | 4,839 | ||
| Deferred offering costs | 1,308 | 1,692 | ||
| Intangible assets, net | 102 | 142 | ||
| Total other assets | 1,410 | 1,834 | ||
| Total assets | 8,066 | 6,673 | ||
| Accounts payable and accrued expenses | 402 | 676 | ||
| Total current liabilities | 402 | 676 | ||
| Common stock, par value 0.001, 100,000,000 shares authorized 20,821,353 and 13,736,597 shares issued and outstanding, respectively | 21 | 18 | ||
| Additional paid-in capital | 20,540 | 17,478 | ||
| Accumulated deficit | -12,897 | -11,499 | ||
| Total shareholders equity | 7,664 | 5,997 | ||
| Total liabilities and shareholders equity | 8,066 | 6,673 | ||
Kairos Pharma, LTD. (KAPA)
Kairos Pharma, LTD. (KAPA)